Abstract
Radiation recall dermatitis (RRD) is an inflammatory reaction that occurs at previously irradiated skin regions after drug administration. We herein report a patient with non-small-cell lung cancer treated previously with thoracic radiotherapy who developed severe RRD induced by atezolizumab [anti-programmed death 1 ligand 1 (PD-L1) antibody]. Immunohistochemistry of the skin biopsy showed dermatitis with infiltration of CD8+ lymphocytes, suggesting that atezolizumab might provoke an immune-related inflammatory reaction at previously irradiated skin regions. When administering anti-PD-L1 antibody to patients who have undergone radiotherapy previously, physicians should carefully monitor the irradiated skin for the potential occurrence of RRD.
Author supplied keywords
Cite
CITATION STYLE
Nakashima, K., Saruwatari, K., Sato, R., Imamura, K., Kajihara, I., Fukushima, S., … Sakagami, T. (2020). Non-small-cell Lung Cancer with Severe Skin Manifestations Related to Radiation Recall Dermatitis after Atezolizumab Treatment. Internal Medicine, 59(9), 1199–1202. https://doi.org/10.2169/internalmedicine.3937-19
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.